Cryptococcal meningoencephalitis in an IgG2-deficient patient with multiple sclerosis on fingolimod therapy for more than five years – case report

Cryptococcal meningoencephalitis in an IgG2-deficient patient with multiple sclerosis on fingolimod therapy for more than five years – case report

Abstract Background Fingolimod (Gilenya®), a first-in-class sphingosine-1-phosphate receptor modulator is approved for the treatment of relapsing-remitting multiple sclerosis. Fingolimod-induced selective immunosuppression leads to an increased risk of opportunistic infections such as cryptococcosis...

Full description

Bibliographic Details
Main Authors: Tobias Wienemann, Ann-Kristin Müller, Colin MacKenzie, Carina Bielor, Vivien Weyers, Orhan Aktas, Hans-Peter Hartung, David Kremer
Format: Article
Language:English
Published: BMC 2020-04-01
Series:BMC Neurology
Subjects:
Cryptococcus
Meningoencephalitis
Multiple sclerosis
Fingolimod
Blood culture
Online Access:http://link.springer.com/article/10.1186/s12883-020-01741-0

Internet

http://link.springer.com/article/10.1186/s12883-020-01741-0

Similar Items